Member Info for KingHomerJ

Agree on this Laura…pretty obvs with the spread £100 would probs turn it blue haa

Sienna - you have no idea what you are talking about.

The new offices are £50k cheaper than the last ones so downsized

Also you don’t have any shares here and when you did it was 90 quids worth.

Yawn….

What annoys me is they going on like it’s been brilliant…that worries me…. It’s been far from it….

I hope the appointment is a good move but atm I can only see significant costs … presumably they know the pipeline…..

The company needs to have more coms with shareholders and investors and actually answer questions that are presented to them.

I do believe there is contracts on route though

There is massive value down here at these prices…imo

BOD have under delivered absolutely and have let all investors down and as you are probably all aware… it may need a new CEO to build investors confidence again???

But either way there value here absolutely

I'd hope so.... Historically they have.

They have put contract awards out on the 22nd December previously then a few in Jan ????

If you read the link it also mentions project optimus

BT7480 PYC has RNS'd and worked on numerous contracts

BT7480 is a Nectin-4 targeted CD137 agonist designed to overcome immune agonist toxicities and activate the immune system in Nectin-4 expressing tumors. Clinical development has been guided by safety considerations observed with first-generation CD137 agonists, the novelty of the Bicycle® platform technology and the U.S. Food and Drug Administration’s (FDA) Project Optimus initiative. In a Phase 1 clinical trial, BT7480 showed:

In 33 patients assigned to receive one of 9 different doses of BT7480, an emerging differentiated safety and tolerability profile with a low number of severe adverse events. The majority of the patients studied had tumors that expressed Nectin-4 and CD137.

Two unconfirmed partial responses in heavily pre-treated patients with cervical cancer.

Three prolonged stable disease (≥7 months) in NSCLC and anal cancer.

Bicycle Therapeutics will continue to define the recommended Phase 2 dose (or maximum dose) and dose range for BT7480, with a view to enroll combination cohorts with checkpoint inhibitors in 2024. These data will inform the design of a Phase 2 trial that could support potential accelerated approval of BT7480.

Https://www.businesswire.com/news/home/20231214384646/en/Bicycle-Therapeutics-Provides-Data-Updates-for-Three-Clinical-Programs-and-Strategy-Overview-at-First-RD-Day

Great update form Bicycle - All of which PYC has worked/working on - AS they looking to develop these assets towards commercialisation it would indicate in my view PYC will gain further contracts .

Intro - Further info on Link

“During our first R&D Day, we are excited to showcase the advantages of our Nobel Prize-winning science and our strategy to discover and develop therapies with greater tolerability that could provide enhanced benefit to a multitude of patients, starting with those who have cancer,” said Kevin Lee, Ph.D., CEO of Bicycle Therapeutics. “Through our Nectin-4 and EphA2 portfolios and the continued work on our platform, including through partnerships, we are building a leading precision-guided therapeutics company with the potential to address a wide range of diseases that affect millions of people around the world. We believe that our technology has the potential to not only help patients live longer but also to live well.”

“Today we are excited to provide clinical updates for our three lead programs,” said Santiago Arroyo, M.D., Ph.D., Chief Development Officer of Bicycle Therapeutics. “In totality, the data support the emerging differentiated profile of our Bicycle® molecules, paving the way to deliver best-in-class or first-in-class therapies for many cancers. Based on our clinical updates, we are taking important next steps with our development programs, setting up what we expect to be a catalyst-rich 2024.”

VALIPHARMA LTD is also funded by VAL PLC and Owe VAL £2.5 Million ????

Valiseek LTD last accounts is a interesting Read..... Owe VAL PLC a million

With Gerry Desler Invoicing Valiseek LTD from his own company?????

Believe so - they will be giving a business update at the below presentation today...

Just exposure in my view

I would have thought we would have some exposure here as we have work with Bicycle for years on numerous projects...

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that the company will host its first Research and Development (R&D) Day on Thursday, December 14. The event will take place in New York City from 8 a.m. to 12 p.m. Eastern Time and will be simultaneously webcast.

Bicycle Therapeutics executives will provide investors and analysts with an overview of the company’s R&D strategy and pipeline opportunities, with an emphasis on clinical updates for BT8009, BT5528 and BT7480. The company will also highlight the broad capabilities of its novel Bicycle® platform technology.

Sorry if It’s been posted - Tim Corn one of PYC non exec been made CMO of Oxford Cannabinoid Technologies

I seem to remember the presentation stated 20% of contract value …

VAL and PYC have a very very close relationship Christopher Chassignol is on the Val Advisory board - not like we have heard anything from that.

Personally they are too close imo

Physiomics plc (AIM: PYC), a leading mathematical modelling company supporting oncology drug development and personalised medicine solutions, announces the signature of a Collaborative Services Agreement with ValiRx's wholly owned subsidiary Inaphaea BioLabs Limited.

The agreement recognises the synergy between Inaphaea's growing capabilities as a translational contract research organisation (tCRO®) providing in-vitro laboratory-based services and Physiomics' in-silico capabilities for advanced statistical analyses, machine learning techniques, data handling and visualisation, as well as biological modelling.

Under the agreement, service users of Inaphaea will be able to benefit from Physiomics capabilities in a single service contract with Inaphaea. Designed to offer a seamless integration of data generation and data interpretation, this collaborative method of working provides benefits to both companies as well as to the service users.

Dr Jim Millen, CEO at Physiomics commented "The Collaborative Service Agreement will expand the scope of our core consulting business to discovery stage projects and improve our access to clients focused on earlier stages of drug development, while at the same time supporting Inaphaea's own service offering. The synergy is clear and both the scientific and commercial ambitions of our two companies are well matched. We look forward to working closely with ValiRx through this initiative"

Dr Suzy Dilly, CEO at ValiRx explains "The Collaborative Services Agreement is the first step towards converting Inaphaea into a true tCRO®. The Physiomics modelling skills will enable our clients to interpret and build on the data generated within the Inaphaea facility. I am delighted to be able to offer this additional service module to our clients. This additional value-added service will be available to our first service users, with benefits expected to increase as more complex data generation technologies are added to our capabilities"

This announcement is released by Physiomics plc and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

“Syneos Health provides mission-critical clinical research and commercialization services to leaders in the biopharmaceutical space,”

Syneos Health SYNH recently entered into a definitive agreement to be acquired by a private investment consortium in an all-cash transaction of approximately $7.1 billion. The consortium of private investment firm affiliates includes Elliott Investment Management, Patient Square Capital and Veritas Capital.

MAY 2023

Depends on broker but yes is the answer.

Need to remember this ?

Our new COO

Dr Sargent held a senior management role at global consultancy business Syneos Health Inc (NASDAQ: SYNH)

Syneos Health was taken private and bought out for 7 billion dollars in May 2023

Precision Dosing Tool / Application for the treatment of Prostate Cancer currently under Trial and supported by UKRI

The FDA - From the regulatory perspective, AI/ML-based solutions can be considered medical devices (i.e., Software as Medical Device, SaMD)

Bit worrying that someone can be so angry and obsessed…

I give zero about there opinion anyway

The grant is for an ongoing product that needs. Validation which is industry norm.

The article was from yesterday!!!